Vyvgart Efgartigimod Alfa Application Scope

Vyvgart (Efgartigimod Alfa) is approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive.

It is a novel immunotherapy that targets and modulates the Fc receptor to reduce autoantibody levels in patients with gMG. By lowering the levels of antibodies that attack the neuromuscular junction, Vyvgart helps improve muscle strength and reduce fatigue in gMG patients, significantly enhancing their quality of life.

Vyvgart is also being studied for use in other autoimmune diseases, including immune thrombocytopenia and other complement-mediated disorders.

Vyvgart Efgartigimod Alfa Characteristics

Ingredients:
- Active ingredient: Efgartigimod Alfa (a recombinant immunoglobulin G1 Fc fragment).
- Excipients: Includes stabilizers and other inactive ingredients.
Properties:Efgartigimod Alfa works by binding to the Fc receptor of macrophages, modulating their activity to reduce the destruction of autoantibodies responsible for autoimmune diseases. It targets the IgG antibodies that attack the neuromuscular junction in gMG patients and reduces their activity, improving muscle strength.
Specification:Available as a solution for intravenous infusion, usually in 10 mg/mL vials.
Storage:
- Store in a refrigerator between 2°C and 8°C. Do not freeze.
- Protect from light.
Expiry Date:Typically 24 months from the manufacturing date (check packaging for exact expiry dates).
Executive Standard:Meets FDA or EMA approval for biologics.
Approval Number:Specific approval details from the FDA or other regulatory bodies.
Manufacturer:argenx, the manufacturer of Vyvgart.

Guidelines For The Use Of Vyvgart Efgartigimod Alfa

Dosage and Administration:

Vyvgart is administered as an IV infusion at a typical dose of 10 mg/kg body weight, given every 2 weeks for the first 4 weeks, followed by maintenance doses every 4 weeks.
The infusion time can vary depending on the patient’s response and tolerability.

Adverse Reactions:

Common side effects include headache, nasopharyngitis, upper respiratory tract infections, and infusion-related reactions.
Serious side effects may include hypersensitivity reactions (e.g., anaphylaxis), infection, and reduced immunity.

Medication Limitations

Contraindications:

Hypersensitivity to Efgartigimod Alfa or any of its components.
Contraindicated in patients with severe infections or immunodeficiencies.

Precautions:

Monitor for infections, as the drug modulates immune system activity.
Use with caution in patients with active or chronic infections.
Patients may require pre-medication for infusion reactions.

Vyvgart Efgartigimod Alfa Interactions

Drug Interactions:Vyvgart may interact with other immunosuppressive therapies or biologic drugs. Care should be taken when used in combination with other drugs affecting the immune system.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.